

=> d his

(FILE 'HOME' ENTERED AT 11:31:09 ON 16 JUN 2005)

FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, RDISCLOSURE,  
USPATFULL, USPAT2' ENTERED AT 11:34:14 ON 16 JUN 2005

E BOEHRINGER/PA

L1 9881 S E3-E12  
L2 1296 S L1 AND (?NEOPLASTIC OR ANTI(W)TUMOR? OR ANTITUMOR? OR CANCER#  
L3 2 S L2 AND (AROMATASE OR EXEMESTANE OR FORMESTANE OR ANASTROZOLE  
L4 4906 S (AROMATASE OR EXEMESTANE OR FORMESTANE OR ANASTROZOLE OR LET  
L5 4275 S L4(L) (?NEOPLASTIC OR ANTI(W)TUMOR? OR ANTITUMOR? OR CANCER#

FILE 'REGISTRY' ENTERED AT 12:34:39 ON 16 JUN 2005

E EPIRUBICIN/CN

L6 1 S E3

FILE 'CAPLUS' ENTERED AT 12:37:13 ON 16 JUN 2005

L7 2312 S L6 OR EPIRUBICIN OR EPIADRIAMYCIN OR EPIDOXORUBICIN OR FARMA

FILE 'REGISTRY' ENTERED AT 12:38:50 ON 16 JUN 2005

E DOCETAXEL/CN

L8 1 S E3

FILE 'CAPLUS' ENTERED AT 12:39:55 ON 16 JUN 2005

L9 3200 S L8 OR DOCETAXEL OR RP(W)56976 OR TAXOTERE OR ?DEACETYLTAXOL

FILE 'REGISTRY' ENTERED AT 12:41:19 ON 16 JUN 2005

E EXEMESTANE/CN

L10 1 S E3

FILE 'CAPLUS' ENTERED AT 12:42:13 ON 16 JUN 2005

L11 343 S L10 OR AROMASIN OR EXEMESTANE OR FCE(W)24304

L12 2 S L11(L) (L9 OR L7)

FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, RDISCLOSURE,  
USPATFULL, USPAT2' ENTERED AT 12:59:02 ON 16 JUN 2005

L13 1163 S L12

L14 1108 DUP REM L13 (55 DUPLICATES REMOVED)

FILE 'USPATFULL, USPAT2' ENTERED AT 13:02:35 ON 16 JUN 2005

L15 529 S L13

L16 1 S L15 NOT PY>=1999

L17 6 S L15 NOT PY>=2001

L18 43 S L15 NOT PY>=2003

L19 13 S L15 NOT PY>=2002

L20 0 S L10(L) (?NEOPLASTIC OR ANTI(W)TUMOR? OR ANTITUMOR? OR CANCER#

L21 612 S L11(L) (?NEOPLASTIC OR ANTI(W)TUMOR? OR ANTITUMOR? OR CANCER#

L22 520 S L21(L) (BREAST)

L23 20 S L22 NOT PY>=2002


=> s e3

L10 1 EXEMESTANE/CN

=> d rn str cn

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 107868-30-4 REGISTRY

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Androsta-1,4-diene-3,17-dione, 6-methylene- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 6-Methyleneandrosta-1,4-diene-3,17-dione

CN Aromasin

CN **Exemestane**

CN FCE 24304

5/4/177


=> s e3

L8 1 DOCETAXEL/CN

=> d rn str cn

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 114977-28-5 REGISTRY

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Benzenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

CN Benzenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2a $\alpha$ ,4 $\beta$ ,4a $\beta$ ,6 $\beta$ ,9 $\alpha$ ( $\alpha$ R\*, $\beta$ S\*),11 $\alpha$ ,12 $\alpha$ ,12a $\alpha$ ,12b $\alpha$ ]]-

OTHER NAMES:

CN **Docetaxel**


CN N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol

CN RP 56976

CN Taxotere

514/449, 450  
514/468 570

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-

OTHER NAMES:

CN 4'-epi-Adriamycin  
CN 4'-epi-Doxorubicin  
CN 4'-Epi-DX  
CN 4'-Epiadriamycin  
CN 4'-Epidoxorubicin  
CN Epiadriamycin  
CN Epidoxorubicin  
CN **Epirubicin**  
CN Farmarubicin  
CN Farmarubicine  
CN IMI 28  
CN NSC 256942  
CN Pharmarubicin  
CN Pidorubicin  
CN WP 697

54/468

=> s l11(1) (19 or 17)  
L12 2 L11(L) (L9 OR L7)

=> d ibib 1-2

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:184907 CAPLUS  
DOCUMENT NUMBER: 136:241643  
TITLE: Exemestane as chemopreventing agent  
INVENTOR(S): Di Salle, Enrico; Piscitelli, Gabriella; Massimini, Giorgio; Purandare, Dinesh; Martini, Alessandro; Muggetti, Lorena  
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy; Pharmacia & Upjohn Company  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020020	A1	20020314	WO 2001-EP10172	20010831
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2419590	AA	20020314	CA 2001-2419590	20010831
AU 2001089865	A5	20020322	AU 2001-89865	20010831
EP 1317270	A1	20030611	EP 2001-969689	20010831
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001013625	A	20030722	BR 2001-13625	20010831
JP 2004508334	T2	20040318	JP 2002-524504	20010831
NZ 524104	A	20041224	NZ 2001-524104	20010831
ZA 2003001309	A	20040218	ZA 2003-1309	20030218
US 2004024044	A1	20040205	US 2003-363935	20030804
PRIORITY APPLN. INFO.:			US 2000-658052 <i>abandoned</i>	20000908
			WO 2001-EP10172	W 20010831

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:824131 CAPLUS  
DOCUMENT NUMBER: 134:508  
TITLE: Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound  
INVENTOR(S): Di Salle, Enrico; Zaccheo, Tiziana; Tedeschi, Michele  
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069467	A1	20001123	WO 2000-EP3407	20000414
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,			

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1178831 A1 20020213 EP 2000-917084 20000414

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

JP 2003512301 T2 20030402 JP 2000-617927 20000414

PRIORITY APPLN. INFO.:

GB 1999-11582 A 19990518

WO 2000-EP3407 W 20000414

REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

*instant  
priority*  
↓  
*PCT*

=> s 115 not py>=2002  
L19 13 L15 NOT PY>=2002

=> d ibib 1-13

L19 ANSWER 1 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:163200 USPATFULL  
TITLE: Oxindolylquinazoline derivatives as angiogenesis inhibitors  
INVENTOR(S): Thomas, Andrew Peter, Macclesfield, United Kingdom  
Lohmann, Jean-Jacques Marcel, Reims Cedex, France  
Hennequin, Laurent Francois Andre, Reims Cedex, France  
Ple, Patrick, Reims Cedex, France  
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294532	B1	20010925
	WO 9910349		19990304
APPLICATION INFO.:	US 2000-486051		20000503 (9)
	WO 1998-GB2493		19980819
			20000503 PCT 371 date
			20000503 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1997-401972	19970822
	EP 1997-401973	19970822
	EP 1997-401974	19970822

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Kifle, Bruck  
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP  
NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
LINE COUNT: 5042  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:158278 USPATFULL  
TITLE: 4-anilinoquinazoline derivatives  
INVENTOR(S): Thomas, Andrew Peter, Macclesfield, United Kingdom  
Johnstone, Craig, Macclesfield, United Kingdom  
Hennequin, Laurent Francois Andre, Reims Cedex, France  
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)  
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291455	B1	20010918
	WO 9732856		19970912
APPLICATION INFO.:	US 1998-142339		19980908 (9)
	WO 1997-GB550		19970228
			19980908 PCT 371 date
			19980908 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1996-400468	19960305
	EP 1996-401499	19960708
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Balasubramanian, Venkataraman	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP	

NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2457  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:121065 USPATFULL  
TITLE: Attaching agents to tissue with transglutaminase and a  
transglutaminase substrate  
INVENTOR(S): Green, Howard, 82 Williston St., Brookline, MA, United  
States 02146  
Corey, George D., 65 Harding St., Newton, MA, United  
States 02165  
Compton, Bruce J., 30 Cottage St., Lexington, MA,  
United States 02173  
Dijan, Philippe, 170, rue de la Convention, 75015  
Paris, France

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6267957	B1	20010731
APPLICATION INFO.:	US 1999-234358		19990120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71908P	19980120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Naff, David M.	
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1730	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:117017 USPATFULL  
TITLE: Oxindole derivatives  
INVENTOR(S): Thomas, Andrew Peter, Macclesfield, United Kingdom  
Lohmann, Jean-Jacques Marcel, Reims Cedex, France  
Hennequin, Laurent Francois Andre, Reims Cedex, France  
Ple, Patrick, Reims Cedex, France  
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6265411	B1	20010724
	WO 9742187		19971113
APPLICATION INFO.:	US 1998-180310		19981106 (9)
	WO 1997-GB1211		19970502
			19981106 PCT 371 date
			19981106 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1996-400956	19960506
	EP 1996-400957	19960506
	EP 1996-402762	19961217
	EP 1996-402763	19961217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	



LINE COUNT: 5959  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2001:108033 USPATFULL  
TITLE: Chemical compounds  
INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, France  
Hennequin, Laurent Francois Andre, Champigny sur  
Vesles, France  
Thomas, Andrew Peter, Congleton, United Kingdom  
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S.  
corporation)  
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258951	B1	20010710
APPLICATION INFO.:	US 2000-500470		20000209 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-203764, filed on 2 Dec 1998 Continuation of Ser. No. US 1996-768887, filed on 17 Dec 1996, now patented, Pat. No. US 5962458		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5180	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2001:63702 USPATFULL  
TITLE: Use of alkylated iminosugars to treat multidrug  
resistance  
INVENTOR(S): Jacob, Gary S., Creve Coeur, MI, United States  
PATENT ASSIGNEE(S): G.D. Searle & Company, Chicago, IL, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225325	B1	20010501
APPLICATION INFO.:	US 1998-189177		19981110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-65051P	19971110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Jones, Dwayne C.	
LEGAL REPRESENTATIVE:	Senniger, Powers, Leavitt & Roedel	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1991	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2001:18472 USPATFULL  
TITLE: Quinazoline derivatives as VEGF inhibitors  
INVENTOR(S): Thomas, Andrew Peter, Macclesfield, United Kingdom  
Johnstone, Craig, Macclesfield, United Kingdom  
Hennequin, Laurent Francois Andre, Reims Cedex, France  
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184225	B1	20010206
	WO 9730035		19970821
APPLICATION INFO.:	US 1998-125271		19980813 (9)
	WO 1997-GB365		19970210
			19980813 PCT 371 date
			19980813 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1996-400293	19960213
	EP 1996-401756	19960808
	EP 1996-402764	19961217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Schroeder, Ben	
LEGAL REPRESENTATIVE:	Pillsbury Madison & Sutro LLPIntellectual Property Group	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3619	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2000:80885 USPATFULL

TITLE: Taxanes

INVENTOR(S): Swindell, Charles S., Merion, PA, United States  
Shashoua, Victor E., Brookline, MA, United States  
Bradley, Matthews O., Laytonsville, MD, United States  
Webb, Nigel L., Bryn Mawr, PA, United States

PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080877		20000627
APPLICATION INFO.:	US 1997-868476		19970603 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651429, filed on 22 May 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Trinh, Ba K.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1034		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2000:70850 USPATFULL

TITLE: Chemical compounds

INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, France  
Hennequin, Laurent Francois Andre, Champigny sur Vesles, France  
Thomas, Andrew Peter, Congleton, United Kingdom

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)  
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071921		20000606

PRIMARY EXAMINER: Shah, Mukund J.  
ASSISTANT EXAMINER: Kifle, Bruck  
LEGAL REPRESENTATIVE: Pillsbury Madison & Sutro  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
LINE COUNT: 5497  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 13 USPATFULL on STN

ACCESSION NUMBER: 1999:75671 USPATFULL  
TITLE: Taxane compounds and compositions  
INVENTOR(S): Bradley, Matthews O., Laytonville, MD, United States  
Shashoua, Victor E., Brookline, MA, United States  
Swindell, Charles S., Merion, PA, United States  
Webb, Nigel L., Bryn Mawr, PA, United States  
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919815		19990706
APPLICATION INFO.:	US 1996-653951		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Reamer, James H.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1,4		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	940		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 13 OF 13 USPATFULL on STN

ACCESSION NUMBER: 1998:98932 USPATFULL  
TITLE: DHA-pharmaceutical agent conjugates of taxanes  
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States  
Swindell, Charles S., Merion, PA, United States  
Webb, Nigel L., Bryn Mawr, PA, United States  
Bradley, Matthews O., Laytonville, MD, United States  
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:98932 USPATFULL  
 TITLE: DHA-pharmaceutical agent conjugates of taxanes  
 INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States  
 Swindell, Charles S., Merion, PA, United States  
 Webb, Nigel L., Bryn Mawr, PA, United States  
 Bradley, Matthews O., Laytonsville, MD, United States  
 PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD The same is true of DHA-**Taxotere** covalent conjugates, examples of which are presented below. **Taxotere**'s synthesis has been reported extensively in the literature. One example is Kanazawa, A. et al., J. Organic Chem. 1994, Vol. . . .

DETD A solution of **Taxotere** in methylene chloride under argon is mixed with 4-dimethylaminopyridine, dicyclohexylcarbodiimide, and DHA. The reaction mixture is stirred at ambient temperature. . . .

DETD A solution of **Taxotere** in dimethylformamide is mixed at ambient temperature under argon with imidazole and triethylsilyl chloride. The reaction mixture is stirred at. . . is washed with water, saturated aqueous sodium chloride, dried, and concentrated Radial chromatography of the residue is performed to produce **Taxotere**-DHA conjugate 4.

DETD A solution of **Taxotere** in dimethylformamide is mixed at ambient temperature under argon with imidazole and tert-butyldimethylsilyl chloride. The reaction mixture is stirred at. . . is washed with water, saturated aqueous sodium chloride, dried, and concentrated Radial chromatography of the residue is performed to produce **Taxotere**-DHA conjugate 4.

DETD A solution of **Taxotere** in dimethylformamide is mixed at ambient temperature under argon with imidazole and tert-butyldimethylsilyl chloride. The reaction mixture is stirred at. . . is washed with water, saturated aqueous sodium chloride, dried, and concentrated. Radial chromatography of the residue is performed to produce **Taxotere**-DHA conjugate 5.

DETD A solution of **taxotere** in dimethylformamide is mixed at ambient temperature under argon with imidazole and tert-butyldimethylsilyl chloride. The reaction mixture is stirred at. . . is washed with water, saturated aqueous sodium chloride, dried, and concentrated. Radial chromatography of the residue is performed to produce **Taxotere**-DHA conjugate 6.

DETD . . . Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; **Docetaxel**; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflomithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epiropidine; **Epirubicin** Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine;. . .

DETD . . . dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;

APPLICATION INFO.: US 1998-203764 19981202 (9)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-768887, filed on 17  
Dec 1996

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Pillsbury Madison & Sutro, LLP Intellectual Property Group	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5709	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 2000:4808 USPATFULL  
TITLE: Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer  
INVENTOR(S): Roder, Hanno, Ratingen, Germany, Federal Republic of Lowinger, Timothy B., Nishinomiya, Japan  
Brittelli, David R., Branford, CT, United States  
VanZandt, Michael C., Guilford, CT, United States  
PATENT ASSIGNEE(S): Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013646		20000111
APPLICATION INFO.:	US 1998-109131		19980702 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Kifle, Bruck		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 13 USPATFULL on STN  
ACCESSION NUMBER: 1999:121360 USPATFULL  
TITLE: Substituted quinazolines  
INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, France  
Hennequin, Laurent Francois Andre, Champigny sur Vesles, France  
Thomas, Andrew Peter, Congleton, United Kingdom  
PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)  
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962458		19991005
APPLICATION INFO.:	US 1996-768887		19961217 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

dronabinol; duocannycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; **epirubicin**; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; **exemestane**; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; . . .

DETD . . . epoxymexrenone; epristeride; eprosartan; eptastigmine; erdosteine; ersentilide; ersofermin; erythritol; esuprone; etanidazole; etanterol; ethacizin; ethinylestradiol; etizolam; etodolac; etoposide phosphate; etrabamine; everninomicin; examorelin; **exemestane**; fadrozole; faeriefungin; famciclovir; fampridine; fantofarone; faropenem; fasidotril; fasudil; fazarabine; fedotozine; felbamate; fenofibrate; fenoldopam; fenretinide; fenspiride; fenticonazole; fepradinol; ferpifosate sodium; ferristene; . . .

DETD . . . castor oil)/ethanol mixture, which is diluted to final volume with normal saline or 5% dextrose. A 15 mg/ml solution of **taxotere** has been formulated in polysorbate 80 (polyoxyethylene sorbitanmonooleate)/ethanol mixture, diluted with 5% dextrose.